Is Survodutide legal in Australia?

Survodutide in Australia at a glance

Classification and note come from the Survodutide profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.

What this means

• 01

  Survodutide is being studied in registered clinical trials but has not received TGA marketing approval in Australia.

• 02

  Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

• 03

  Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What Survodutide is

An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The glucagon component adds energy expenditure and liver-directed effects to the appetite and glucose benefits of GLP-1.

Mechanism: Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction.

Regulatory history: Investigational, not FDA-approved

How TGA treats this kind of product

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Survodutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Survodutide in other countries

Frequently asked questions

Related compounds in Australia